[1] Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. Menopause. 2021; 28(9):973-997.
[2] BÖRJESSON AE, LAGERQUIST MK, WINDAHL SH, et al. The role of estrogen receptor α in the regulation of bone and growth plate cartilage. Cell Mol Life Sci. 2013;70(21):4023-4037.
[3] BURGE R, DAWSON-HUGHES B, SOLOMON DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22(3):465-475.
[4] WATTS NB. Fundamentals and pitfalls of bone densitometry using dual-energy X-ray absorptiometry (DXA). Osteoporos Int. 2004;15(11):847-854.
[5] LI Y, SHI Z, FENG S. Systematic analysis of miRNAs in patients with postmenopausal osteoporosis. Gynecol Endocrinol. 2020;36(11): 997-1001.
[6] LIU H, ZHAO H, LIN H, et al. Relationship of COL9A1 and SOX9 Genes with Genetic Susceptibility of Postmenopausal Osteoporosis. Calcif Tissue Int. 2020;106(3):248-255.
[7] MA W, CHEN K, XIAO W, et al. Evaluation of relationship between SPON1 gene and genetic susceptibility of postmenopausal osteoporosis. Artif Cells Nanomed Biotechnol. 2020;48(1):818-823.
[8] HU Y, WANG Y, LIU S, et al. The Potential Roles of Ferroptosis in Pathophysiology and Treatment of Musculoskeletal Diseases-Opportunities, Challenges, and Perspectives. J Clin Med. 2023;12(6):2125.
[9] WANG S, WANG H, FENG C, et al. The regulatory role and therapeutic application of pyroptosis in musculoskeletal diseases. Cell Death Discov. 2022;8(1):492.
[10] D’AMELIO P. The immune system and postmenopausal osteoporosis. Immunol Invest. 2013;42(7):544-554.
[11] 陈天宁,杨铁毅,邵进,等.免疫相关基因在绝经后骨质疏松症患者外周血白细胞中的表达[J].中国组织工程研究,2020,24(25):4033-4038.
[12] STOCKWELL BR. Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications. Cell. 2022;185(14):2401-2421.
[13] ZHANG Y, HUANG X, QI B, et al. Ferroptosis and musculoskeletal diseases: “Iron Maiden” cell death may be a promising therapeutic target. Front Immunol. 2022;13:972753.
[14] YU P, ZHANG X, LIU N, et al. Pyroptosis: mechanisms and diseases. Signal Transduct Target Ther. 2021;6(1):128.
[15] TAO Z, WANG J, WEN K, et al. Pyroptosis in Osteoblasts: A Novel Hypothesis Underlying the Pathogenesis of Osteoporosis. Front Endocrinol (Lausanne). 2020;11:548812.
[16] WU D, CLINE-SMITH A, SHASHKOVA E, et al. T-Cell Mediated Inflammation in Postmenopausal Osteoporosis. Front Immunol. 2021;12:687551.
[17] FISCHER V, HAFFNER-LUNTZER M. Interaction between bone and immune cells: Implications for postmenopausal osteoporosis. Semin Cell Dev Biol. 202;123:14-21.
[18] ZHANG D, LI Y, DU C, et al. Evidence of pyroptosis and ferroptosis extensively involved in autoimmune diseases at the single-cell transcriptome level. J Transl Med. 2022;20(1):363.
[19] BIJELIC R, MILICEVIC S, BALABAN J. Risk Factors for Osteoporosis in Postmenopausal Women. Med Arch. 2017;71(1):25-28.
[20] 雷欣东,于慧,龙琼,等.绝经后骨质疏松症发病机制研究进展[J].中国骨质疏松杂志,2021,27(11):1681-1684.
[21] KOU J, ZHENG X, GUO J, et al. MicroRNA-218-5p relieves postmenopausal osteoporosis through promoting the osteoblast differentiation of bone marrow mesenchymal stem cells. J Cell Biochem. 2020;121(2):1216-1226.
[22] 梁学振,谢国鑫,李嘉程,等.基于miRNA-mRNA调控网络股骨头坏死的关键基因筛选与分析[J].中国组织工程研究,2022,26(11):1720-1727.
[23] BURDETTE BE, ESPARZA AN, ZHU H, et al. Gasdermin D in pyroptosis. Acta Pharm Sin B. 2021;11(9):2768-2782.
[24] WANG J, ZHANG H, WANG Y, et al. Severe congenital neutropenia caused by ELANE gene mutation: A case report and literature review. Medicine (Baltim). 2022;101(44):e31357.
[25] RAO S, YAO Y, SOARES DE BRITO J, et al. Dissecting ELANE neutropenia pathogenicity by human HSC gene editing. Cell Stem Cell. 2021;28(5):833-845.e5.
[26] MAKARYAN V, KELLEY M, FLETCHER B, et al. Comparison of Gene Editing versus a Neutrophil Elastase Inhibitor as Potential Therapies for ELANE Neutropenia. J Cell Immunol. 2022;4(1):19-28.
[27] PENG B, HU J, FU X. ELANE: an emerging lane to selective anticancer therapy. Signal Transduct Target Ther. 2021;6(1):358.
[28] FANG Z, CHENG G, HE M, et al. CYP27A1 deficiency promoted osteoclast differentiation. PeerJ. 2023;11:e15041.
[29] ZHANG Y, YANG Y, WANG C, et al. Identification of Diagnostic Biomarkers of Osteoarthritis Based on Multi-Chip Integrated Analysis and Machine Learning. DNA Cell Biol. 2020. doi: 10.1089/dna.2020.5552
[30] JABERI SA, COHEN A, D’SOUZA C, et al. Lipocalin-2: Structure, function, distribution and role in metabolic disorders. Biomed Pharmacother. 2021; 142:112002.
[31] ITO K, YAMAMOTO T, HAYASHI Y, et al. Osteoblast-derived extracellular vesicles exert osteoblastic and tumor-suppressive functions via SERPINA3 and LCN2 in prostate cancer. Mol Oncol. 2023. doi: 10.1002/1878-0261. 13484.
[32] HSU SK, LI CY, LIN IL, et al. Inflammation-related pyroptosis, a novel programmed cell death pathway, and its crosstalk with immune therapy in cancer treatment. Theranostics. 2021;11(18):8813-8835.
[33] LIU J, SONG X, KUANG F, et al. NUPR1 is a critical repressor of ferroptosis. Nat Commun. 2021;12(1):647.
[34] CAPULLI M, PONZETTI M, MAURIZI A, et al. A Complex Role for Lipocalin 2 in Bone Metabolism: Global Ablation in Mice Induces Osteopenia Caused by an Altered Energy Metabolism. J Bone Miner Res. 2018;33(6):1141-1153.
[35] JIANG JH, WANG SY, ZHANG J, et al. LCN2 Inhibits the BMP9-induced Osteogenic Differentiation through Reducing Wnt/beta-catenin Signaling via Interacting with LRP6 in Mouse Embryonic Fibroblasts. Curr Stem Cell Res Ther. 2023;18(8):1160-1171.
[36] YAO Y, CAI X, REN F, et al. The Macrophage-Osteoclast Axis in Osteoimmunity and Osteo-Related Diseases. Front Immunol. 2021;12:664871.
|